Related references
Note: Only part of the references are listed.Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events
Alberto Alvarez-Larran et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients
Holly L. Geyer et al.
BLOOD (2014)
A Phase 2 Study of Ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in Patients With Advanced Polycythemia Vera Who Are Refractory or Intolerant to Hydroxyurea
Srdan Verstovsek et al.
CANCER (2014)
Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials
John Mascarenhas et al.
HAEMATOLOGICA (2014)
Rethinking the diagnostic criteria of polycythemia vera
T. Barbui et al.
LEUKEMIA (2014)
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
P. Guglielmelli et al.
LEUKEMIA (2014)
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
A. Tefferi et al.
LEUKEMIA (2014)
Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: A physician survey
Martin H. Ellis et al.
THROMBOSIS RESEARCH (2014)
Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases
Francesco Dentali et al.
THROMBOSIS RESEARCH (2014)
Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis
Richard T. Silver et al.
BLOOD (2013)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi et al.
BLOOD (2013)
CANCER-ASSOCIATED THROMBOTIC DISEASE Myeloproliferative neoplasms and thrombosis
Tiziano Barbui et al.
BLOOD (2013)
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
Alfonso Quintas-Cardama et al.
BLOOD (2013)
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations
Anthony J. Bench et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
Christen L. Andersen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Splanchnic vein thrombosis in myeloproliferative neoplasms
Mallika Sekhar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
Guido Finazzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
Emil T. Kuriakose et al.
HAEMATOLOGICA (2013)
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis
A. Spolverini et al.
HAEMATOLOGICA (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
J. V. Jovanovic et al.
LEUKEMIA (2013)
Polycythemia Vera, the Hematocrit, and Blood-Volume Physiology
Jerry L. Spivak
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
Elisabetta Antonioli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
Alberto Alvarez-Larran et al.
BLOOD (2012)
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
Jasper H. Smalberg et al.
BLOOD (2012)
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target
Silvia Pascale et al.
BLOOD (2012)
Brief report Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
Tiziano Barbui et al.
BLOOD (2012)
Why Does My Patient Have Erythrocytosis?
Marina Kremyanskaya et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2012)
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
A. Tefferi et al.
LEUKEMIA (2012)
JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis
Valerio De Stefano et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
The JAK2 exon 12 mutations: A comprehensive review
Linda M. Scott
AMERICAN JOURNAL OF HEMATOLOGY (2011)
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
Robyn Scherber et al.
BLOOD (2011)
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
Francesco Passamonti et al.
BLOOD (2011)
New mutations and pathogenesis of myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2011)
The renaissance of interferon therapy for the treatment of myeloid malignancies
Jean-Jacques Kiladjian et al.
BLOOD (2011)
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
Jean-Jacques Kiladjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy
Richard T. Silver et al.
LEUKEMIA RESEARCH (2011)
JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment
Alessandro M. Vannucchi et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2011)
Bone Marrow Morphologic Features in Polycythemia Vera With JAK2 Exon 12 Mutations
Meredith A. Lakey et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count
Ayaew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Stephen T. Oh et al.
BLOOD (2010)
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
Giovanni Barosi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Polycythemia vera-associated pruritus and its management
Kamal S. Saini et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2010)
Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
Min Lu et al.
EXPERIMENTAL HEMATOLOGY (2010)
Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells
J-J Kiladjian et al.
LEUKEMIA (2010)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
LNK Mutations in JAK2 Mutation-Negative Erythrocytosis.
Terra L. Lasho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients
Valerie Ugo et al.
PLOS ONE (2010)
Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
Tiziano Barbui et al.
BLOOD (2009)
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
Giovanni Barosi et al.
BLOOD (2009)
Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients
Alberto Alvarez-Larran et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study
Eric Lippert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera
Susanne Schnittger et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
Damla Olcaydu et al.
NATURE GENETICS (2009)
A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
Outi Kilpivaara et al.
NATURE GENETICS (2009)
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Amy V. Jones et al.
NATURE GENETICS (2009)
Treatment options for essential thrombocythemia and polycythemia vera
Alessandro M. Vannucchi et al.
EXPERT REVIEW OF HEMATOLOGY (2009)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden
Ola Landgren et al.
BLOOD (2008)
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
Jerry L. Spivak et al.
BLOOD (2008)
Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy
Martin Griesshammer et al.
BLOOD REVIEWS (2008)
Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis
Amy V. Jones et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
J-J Kiladjian et al.
LEUKEMIA (2008)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2007)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Raffaele Landolfi et al.
BLOOD (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) - An international internet-based survey of 1179 MPD patients
Ruben A. Mesa et al.
CANCER (2007)
The haematocrit and platelet target in polycythemia vera
Marcello Di Nisio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis
Mary F. McMullin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Pregnancy and its management in the Philadelphia negative myeloproliferative diseases
C Harrison
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
